Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The price of a “life-changing” weight loss drug could double or even triple in the UK by the end of the month, prompting ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly has signed a deal worth US$1.3 billion with privately held Superluminal Medicines to discover and develop ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...